First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
Mingfeng HeTaihao ZhengXiaoyue ZhangYuan PengXuan JiangYusheng HuangBenxu TanZhen Zhou YangPublished in: Cancer immunology, immunotherapy : CII (2021)
The study suggested that chemotherapy plus ICIs might improve PFS and ORR than single-agent ICIs for advanced NSCLC patients with PD-L1 ≥ 50%. However, it did not lead to OS benefit.